Prilenia
PrivateLast Round
Series B
Extension
Apr 12, 2022
Total Funding Raised
$115.5M
Momentum Score
25 /100
Company Overview
Prilenia is a biotechnology company focused on developing treatments for neurodegenerative and neurodevelopmental disorders, offering Pridopidine, a first-in-class oral drug candidate with a proven safety profile that shows promise for various movement disorders and neurodegenerative diseases in both adults and children.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B2C
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prilenia Comps
Public and private peers based on sector, stage, and business model.
Prilenia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 12, 2022 | ||||
| Series B | Nov 3, 2021 | ||||
| Series A | Jun 3, 2020 |
Key People
Founding team and executive leadership
Prilenia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series B Extension |
| Amplitude Ventures | Series B Extension, Series B |
| Morningside Ventures | Series B, Series A |
| Genworks Health | Series A |
| ALS Investment Fund | Series B Extension, Series B |
| Sectoral | Series B, Series A |
| Talisman Capital Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
Elisabeth (Lis) Leiderman, MD, MBA, appointed as CFO.
- Mar 13, 2026
Partnered with Ferrer for co-development and commercialization of pridopidine.
Prilenia Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Prilenia's valuation, stock price, and market status.
